3040 Background: Pembrolizumab was recently FDA approved across solid tumors for TMB
scores≥ 10mut/Mb as assessed by next-generation sequencing (NGS) of tissue (tTMB). A …

Background: The advantages of plasma-based tumor mutational burden (TMB) include non-
invasive, real-time assessment of mutational load, without the limitations of insufficient …

Background Ultra-deep sequencing to detect low-frequency mutations in circulating tumor-
derived DNA (ctDNA) increases the diagnostic value of liquid biopsy. The demand for large …

Background The tumor mutational burden (TMB) is a genomic biomarker associated with the
benefits from immune checkpoint inhibitors (ICIs) cancer therapy. An elevated blood TMB …

e23028 Background: TMB is a potential biomarker for response to checkpoint blockade.
Prior studies have associated tissue TMB with genomic instability and neoantigen binding …

Background: Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) enables
non-invasive profiling of solid tumor cancers. Over the past few years, research and clinical …

2540 Background: Tumor mutational burden (TMB) detected by tissue-based Next
Generation Sequencing (NGS) is a biomarker for immunotherapy (IO) response. Plasma …

PURPOSE Profiling of circulating tumor DNA (ctDNA) is increasingly adopted in the
management of solid tumors, concurrent with increased availability of more comprehensive …

Background: Tumor mutation burden (TMB) has been shown as a new predictive biomarker
for immune checkpoint inhibitor in various cancer types. It is typically measured by …

Background The correlation between blood-based tumor mutation burden (bTMB) and
tissue-based tumor mutation burden (tTMB) has not been broadly tested in a multicancer …